| 000 | 01584 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250513153538.0 | ||
| 264 | 0 | _c19981027 | |
| 008 | 199810s 0 0 eng d | ||
| 022 | _a0263-7103 | ||
| 024 | 7 |
_a10.1093/rheumatology/37.9.952 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBlack, C M | |
| 245 | 0 | 0 |
_aOral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study. _h[electronic resource] |
| 260 |
_bBritish journal of rheumatology _cSep 1998 |
||
| 300 |
_a952-60 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIloprost _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aRaynaud Disease _xclassification |
| 650 | 0 | 4 |
_aScleroderma, Systemic _xcomplications |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aVasodilator Agents _xadministration & dosage |
| 700 | 1 | _aHalkier-Sørensen, L | |
| 700 | 1 | _aBelch, J J | |
| 700 | 1 | _aUllman, S | |
| 700 | 1 | _aMadhok, R | |
| 700 | 1 | _aSmit, A J | |
| 700 | 1 | _aBanga, J D | |
| 700 | 1 | _aWatson, H R | |
| 773 | 0 |
_tBritish journal of rheumatology _gvol. 37 _gno. 9 _gp. 952-60 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/rheumatology/37.9.952 _zAvailable from publisher's website |
| 999 |
_c9748315 _d9748315 |
||